AOL Money & Finance

Analyst initiations 12-29-06: Pharmaceuticals Noven & Pozen take top honors

More

Given the last day of the trading for 2006, initiations were light.

  • Baird initiated Noven Pharmaceuticals (NASDAQ: NOVN) with an Outperform and $30 target, based on the Daytrana, which Baird believes should be a driver for shares with continued success, milestones and improved profitability.
  • Also initiated by Baird, POZEN Inc (NASDAQ: POZN) with an Outperform rating and $26 target; they expect Pozen's Trexima to be approved in mid-2007 and for their marketing partner, GlaxoSmithKline plc ADR (NYSE: GSK), to convert 60% of Imitrix market share to Trexima.
  • Thomas Weisel initiated Hansen Medical (NASDAQ: HNSN) with an Overweight rating and $14.50 target; the firm is positive on the Sensai platform, a robotic catheter control system, which allows unprecedented control and enables new procedures to become minimally invasive.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).
Symbol Lookup
IndexesChangePrice
DJIA+73.0010,270.47
NASDAQ+18.862,167.88
S&P 500+6.241,093.48

Last updated: November 14, 2009: 07:28 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines